NeoImmuneTech said it would disclose the interim results of a trial of NT-I7 (efineptakin alfa), a T-cell amplifier, in combination with an immune checkpoint inhibitor at the annual meeting of the Society for Immunotherapy of Cancer (SITC) in the U.S. in November.

NeoImmuneTech’s study was selected as an oral presentation during the “Next-Generation Cytokine Therapy” session of the SITC event.

Researchers will share insights on notable cytokines as anticancer treatments during the session.

The topic and the explicit content will be revealed after Oct. 5, when SITC 2022 opens the themes of abstracts.

The annual meeting of SITC will take place from Nov. 8-12 in Boston, the U.S. NeoImmuneTech will provide the oral presentation for 15 minutes from 4:20 p.m. on Nov. 11.

NT-I7 has demonstrated therapeutic potential in intractable diseases such as pancreatic cancer and microsatellite stable colon cancer, where immune checkpoint inhibitors alone did not produce good outcomes.

NeoImmuneTech’s NT-I7 was picked for a poster discussion session at the American Society of Clinical Oncology meeting in June.

The company said NT-I7 showed 40.7 percent and 34.6 percent disease control rate (CDR) in pancreatic and MSS colon cancer, respectively. In addition, the company said that the tumor size shrank 100 percent and 72 percent in two pancreatic cancer patients, raising expectations for NT-I7 to extend the survival of cancer patients, the company said.